Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
59 hedge funds and large institutions have $355M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 21 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
29% more capital invested
Capital invested by funds: $275M → $355M (+$80.3M)
20% more funds holding
Funds holding: 49 → 59 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$15.3M |
| 2 |
BlackRock
New York
|
+$6.94M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$4.9M |
| 4 |
JP Morgan Chase
New York
|
+$3.43M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.96M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.75M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.12M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.9M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$1.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FMA
76
FNY Managed Accounts
New York
| – | -$153K | -8,100 | Closed |
|
77
SG Americas Securities
New York
| – | -$143K | -7,544 | Closed |
|
|
PCM
78
Prelude Capital Management
New York
| – | -$31K | -1,613 | Closed |
|
79
Credit Agricole
Montrouge Cedex,
France
| – | -$19K | -1,000 | Closed |
|
|
CCA
80
Catalyst Capital Advisors
Huntington,
New York
| – | -$6K | -305 | Closed |
|
DCPH Hedge Fund Activity: Q4 2017 in Review
59 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2017, worth a combined $355M — up 29% from $275M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new DCPH positions and 21 closed out — a net gain of 10 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was OrbiMed, adding an estimated $15.3M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.96M sold.
- 59 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2017, up from 49 in Q3 2017.
- Funds reported $355M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 29% quarter-over-quarter.
- 31 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 21 closed out, a net change of +10 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was OrbiMed, an estimated $15.3M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Citadel Advisors, an estimated $4.96M sold.
Based on aggregated 13F filings for Q4 2017.